15 March 2023 in Nature Communications
Cannabinoid CB2 receptor (CB2R) agonists are investigated as therapeutic agents in the clinic. However, their molecular mode-of-action is not fully understood. Here, we report the discovery of LEI-102, a CB2R agonist, used in conjunction with three other CBR ligands (APD371, HU308, and CP55,940) to investigate the selective CB2R activation by binding kinetics, site-directed mutagenesis, and cryo-EM studies. We identify key residues for CB2R activation. Highly lipophilic HU308 and the endocannabinoids, but not the more polar LEI-102, APD371, and CP55,940, reach the binding pocket through a membrane channel in TM1-TM7. Favorable physico-chemical properties of LEI-102 enable oral efficacy in a chemotherapy-induced nephropathy model. This study delineates the molecular mechanism of CB2R activation by selective agonists and highlights the role of lipophilicity in CB2R engagement. This may have implications for GPCR drug design and sheds light on their activation by endogenous ligands.
22 February 2024 in ChemRxiv
The cannabinoid receptor type 1 (CB1R) is one of the central elements of the endocannabinoid system regulating a variety of signaling cascades. Extensive efforts on CB1R have validated its essential roles in physiology such as appetite regulation, pain perception, memory formation, and thermoregulation. Yet, there is a surprising lack of clear understanding of its cellular signaling, distribution, and expression dynamics. CB1R visualization in real-time is therefore crucial for addressing these open questions in cannabinoid research. Using various highly selective drug-like CB1R ligands with a defined pharmacological profile, we investigated their potential for constructing CB1R fluorescent probes by a reverse design-approach. A modular design concept with a diethyl glycine-based building block as centerpiece allowed the straightforward modular synthesis of novel probe candidates. Supported by computational docking studies, this systematic approach led to the identification of novel pyrrole-based CB1R fluorescent probes. The probes demonstrated CB1R selectivity in radioligand binding profiling and inverse agonist activity in a cAMP assay. Application in time-resolved fluorescence resonance target-engagement studies and CB1R live cell imaging exemplify the great versatility of the tailored pyrrole-based fluorescent probes. These validated fluorescent probes aim to deepen the understanding of mechanistic aspects of CB1R localization, trafficking, and activation essential for the function and role of this receptor in pathological conditions.
18 March 2026 in Chemical Science
This study, exemplified at CB 2 R, showcases how strategic reutilization of a single ligand scaffold fine-tunes activity of a class A GPCR by virtue of targeting its toggle switch.
16 January 2024 in ChemRxiv
The diversity of physiological roles of the endocannabinoid system has turned it into an attractive yet elusive therapeutic target. However, chemical probes with various functionalities could pave the way for a better understanding of the endocannabinoid system at the cellular level. Notably, inverse agonists of CB2R – a key receptor of the endocannabinoid system - lagged behind despite the evidence regarding the therapeutic potential of its antagonism. Herein, we report a matched fluorescent probe pair based on a common chemotype to address and visualize both the active and inactive states of CB2R, selectively. Alongside with extensive cross-validation by flow cytometry and confocal microscopy, we successfully visualize the intracellular localization of CB2R pools in live cells. The synthetic simplicity together with the high CB2R-selectivity and specificity of our probes, turn them into valuable tools in chemical biology and drug development that can benefit the clinical translatability of CB2R-based drug.
26 October 2023 in ChemRxiv
We report the structure-based design of cannabinoid receptor type 2 (CB2R)-selective inverse agonists (S)-1 and (R)-1, which were derived from privileged agonist HU-308 by introduction of a phenyl group at the gem-dimethylheptyl sidechain. Epimer (R)-1 exhibits high affinity for CB2R with Kd = 39 nM and serves as a platform for the synthesis of a wide variety of probes. Notably, the fluorescent probes, for the first time, retain their inverse agonist functionality, high affinity, and selectivity for CB2R independent of linker and fluorophore substitution. Ligands (S)-1, (R)-1, and their derivatives act as inverse agonists in CB2R-mediated cAMP as well as G protein recruitment assays, and do not trigger β-arrestin–receptor association. Furthermore, no receptor activation was detected in live cell ERK1/2 phosphorylation and Ca2+-release assays. Confocal fluorescence imaging experiments with (R)-7 (Alexa488) and (R)-9 (Alexa647) probes employing BV-2 microglial cells visualized CB2R expressed at endogenous levels. Finally, molecular dynamics simulations corroborate the initial docking data in which inverse agonists restrict movement of toggle switch, Trp2586.48, and thereby stabilize CB2R in its inactive state. The present study serves as a blueprint for the rational design of GPCR ligands beyond CB2R with a tailored functional response.